GlassScriptPhysician profile
Radomir Stevanovic
NPI 1508883208
$1,472.11
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $382 · 2021: $645 · 2022: $176.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $272.69 | 2019-2022 | |
| Pfizer INC. | $116.66 | 2019-2022 | |
| Amgen INC. | $92.47 | 2019-2022 | |
| Lilly USA, LLC | $86.73 | 2019-2022 | |
| Abbvie INC. | $77.67 | 2021 | |
| Merck Sharp & Dohme LLC | $71.39 | 2019-2021 | |
| Medtronic Minimed, INC. | $68.89 | 2020 | |
| Janssen Pharmaceuticals, INC | $57.95 | 2021 | |
| Glaxosmithkline, LLC. | $56.15 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $54.70 | 2021 | |
| Sanofi-Aventis U.S. LLC | $50.95 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $35.83 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.41 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.55 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.52 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.92 | 2019 | |
| Esperion Therapeutics, INC. | $14.30 | 2020 | |
| Mylan Specialty L.P. | $14.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.26 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Radomir Stevanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.